Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry

Christian Veltmann; Stefan Winter; David Duncker; Carsten Jungbauer; Nadine K. Wäßnig; J. Christoph Geller; Julia W. Erath; Olaf Goeing; Christian Perings; Michael Ulbrich; Mattias Roser; Daniela Husser; Laura Gansera; Korkut Soezener; Frank Michael Malur; Michael S. Block; Thomas Fetsch; Valentina Kutyifa; Helmut Klein

doi:10.1007/s00392-020-01657-2

Figures

Why the study?

Does the wearable cardioverter-defibrillator (WCD) improve selection for ICD implantation in patients with HFrEF and a potential risk of sudden arrhythmic death?

Key Points

To assess the role of the wearable cardioverter-defibrillator in monitoring ejection fraction progression and competing mortality risks to refine candidate selection for permanent implantable cardioverter-defibrillators.
Analyzed patient data from the multicenter WEARIT-II-EUROPE registry.
Evaluated left ventricular ejection fraction trajectory and causes of death during the wearable cardioverter-defibrillator prescription period.
Mortality during wearable cardioverter-defibrillator wear was primarily driven by progressive heart failure and non-cardiovascular causes rather than sudden arrhythmic death.
Protected monitoring enabled identification of left ventricular ejection fraction changes and competing mortality risks, refining selection for implantable cardioverter-defibrillator therapy.

Structured PICO

Does the wearable cardioverter-defibrillator (WCD) improve selection for ICD implantation in patients with HFrEF and a potential risk of sudden arrhythmic death?

P

Population

Patients with HFrEF and a potential risk of sudden arrhythmic death

I

Intervention

Wearable cardioverter-defibrillator (WCD)

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

In HFrEF patients at risk of sudden arrhythmic death, WCD use allows for protected observation of LVEF progression and competing risks, potentially improving selection for ICD implantation.

Abstract

Mortality after WCD prescription was mainly driven by heart failure and non-cardiovascular death. In patients with HFrEF and a potential risk of sudden arrhythmic death, WCD protected observation of LVEF progression and appraisal of competing risks of potential non-arrhythmic death may enable improved selection for beneficial ICD implantation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Veltmann et al. (2020) studied this question.

synapsesocial.com/papers/69d77904b843b2be9948fee5 https://doi.org/10.1007/s00392-020-01657-2

View Full Paper

Ask AI

Bookmark

Share

Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry

Figures

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry

Figures

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading